Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Splicing01:32

RNA Splicing

57.5K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
57.5K
Alternative RNA Splicing02:18

Alternative RNA Splicing

21.9K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.5K
Pre-mRNA Processing: RNA Splicing01:36

Pre-mRNA Processing: RNA Splicing

5.6K
5.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deciphering the Functional Mechanisms of eIF3f in Tumors and Exploring Targeted Therapies.

Pharmacology research & perspectives·2026
Same author

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
Same author

Inhibition of NHE1 induces trophoblast cell senescence via ADGRG6 mediated by CXCL8.

Journal of reproductive immunology·2026
Same author

Association Between Polymorphisms of 4 Common Genes and High Myopia Risk: A Comprehensive Analysis.

Medical science monitor : international medical journal of experimental and clinical research·2026
Same author

Neuroprotective effects of traditional Chinese medicine using zebrafish models - a review.

Frontiers in pharmacology·2026
Same author

FTO-modulated m<sup>6</sup>A demethylation and upregulation of KIF11 mRNA promotes retinal microvascular dysfunction in diabetic retinopathy.

Journal of translational medicine·2026
Same journal

Advancing fat graft survival: from adipose-derived stem cell mechanisms to next-generation regenerative strategies.

Frontiers in cell and developmental biology·2026
Same journal

CRISPR-based next-generation molecular diagnostics for bone infection.

Frontiers in cell and developmental biology·2026
Same journal

Tissue turnover and rejuvenation through mechanics.

Frontiers in cell and developmental biology·2026
Same journal

Decoding signaling crosstalk in pulpitis: pathogenesis and precision therapeutics.

Frontiers in cell and developmental biology·2026
Same journal

Embryonic scaling: morphogen gradients, size sensing, and scaler genes.

Frontiers in cell and developmental biology·2026
Same journal

H<sub>2</sub>S-mediated protein S-sulfhydration: a novel regulatory module in lipid metabolism.

Frontiers in cell and developmental biology·2026
See all related articles

Related Experiment Video

Updated: Oct 9, 2025

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.1K

Targeting Splicing Factor SRSF6 for Cancer Therapy.

Wenting She1,2, Jun Shao3, Rong Jia1

  • 1The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, China.

Frontiers in Cell and Developmental Biology
|December 17, 2021
PubMed
Summary
This summary is machine-generated.

Aberrant alternative splicing is a cancer hallmark. Serine/arginine-rich splicing factor 6 (SRSF6) promotes oncogenic splicing when overexpressed, suggesting it

Keywords:
SRSF6alternative splicingcancer therapyoncogeneoverexpression

More Related Videos

Using the E1A Minigene Tool to Study mRNA Splicing Changes
10:25

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

5.1K
A Reporter Based Cellular Assay for Monitoring Splicing Efficiency
08:53

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

Published on: September 15, 2021

2.9K

Related Experiment Videos

Last Updated: Oct 9, 2025

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.1K
Using the E1A Minigene Tool to Study mRNA Splicing Changes
10:25

Using the E1A Minigene Tool to Study mRNA Splicing Changes

Published on: April 22, 2021

5.1K
A Reporter Based Cellular Assay for Monitoring Splicing Efficiency
08:53

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

Published on: September 15, 2021

2.9K

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Aberrant alternative splicing is a key feature in cancer development.
  • Splicing factors regulate gene expression by controlling alternative splicing.
  • Serine/arginine-rich splicing factor 6 (SRSF6) influences splicing of numerous cancer-associated genes.

Purpose of the Study:

  • To review the structure, expression, and function of SRSF6 in cancer.
  • To summarize the regulatory mechanisms of SRSF6 in tumorigenesis.
  • To discuss SRSF6 as a potential therapeutic target in cancer treatment.

Main Methods:

  • Literature review of studies on SRSF6 and cancer.
  • Analysis of SRSF6 gene, mRNA, and protein structure.
  • Summary of experimental evidence on SRSF6 function and regulation.

Main Results:

  • SRSF6 is overexpressed in many cancers.
  • SRSF6 promotes the production of oncogenic splicing isoforms.
  • SRSF6 plays a significant role in promoting tumorigenesis.

Conclusions:

  • SRSF6 is an oncogenic splicing factor.
  • Targeting SRSF6 holds promise for cancer therapy.
  • Further research into SRSF6 regulation and targeting is warranted.